---

Chi Van Dang

Scientific Director, Ludwig Cancer Research

Chi is well-known for his contributions to the understanding of the Myc oncogene – his research has led to studies dedicated to the targeted disruption of aberrant cell metabolic pathways, with the aim of developing drugs to inhibit cancer. “Patients dying of cancer remind me every day why I do what I do. As with everyone else, my life has been personally touched by cancer, and as a trained medical oncologist, I am humbled by cancer as a formidable foe. A career is a journey in continuous learning – I learn something new every day.”

---

Part of the Power List 2018

The World’s Top 100 Medicine Makers

Bringing new drugs to patients is an incredibly difficult task that involves numerous indispensable actors – from pioneering entrepreneurs and CEOs, to industry experts, to dedicated researchers, to regulators who keep everyone on the right tracks.

Go to The Power List 2018